medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 5

<< Back Next >>

Med Int Mex 2022; 38 (5)

Diffuse alveolar hemorrhage secondary to microscopic polyangiitis

Zenteno-Lange R, Frías-Abrahamov M, Lule-Morales M, Guamán-Crespo J

Language: Spanish
References: 37
Page: 1119-1131
PDF size: 318.41 Kb.


ABSTRACT

Background: Patients with microscopic polyangiitis have organ multisystemic involvement. Alveolar hemorrhage is seen with some frequency, and can be injured simultaneously the kidney, musculoskeletal, and others. The diagnostic approach in a critically ill patient can be affected by large number of factors caused by complications of hospitalization in an intensive care unit.
Clinical case: A 66-year-old female patient with diffuse alveolar hemorrhage secondary to microscopic polyangiitis.
Conclusions: Being a non-frequent entity, microscopic polyangiitis requires minimal clinical suspicion to start the diagnostic approach with paraclinical examinations according to the presentation of the disease, with computed tomography, bronchoscopy with bronchioalveolar lavage before suspected diffuse alveolar hemorrhage; and/or renal biopsy in the case of acute kidney injury with urine sediment. There is currently medical treatment that allows to obtain an adequate clinical response. In addition, new therapies are specifically found to improve clinical outcomes and reduce adverse effects associated with treatment.


REFERENCES

  1. Arman F, Barsoum M, Selamet U, Shakeri H, Wassef O,Mikhail M. Antineutrophil cytoplasmic antibody-associatedvasculitis, update on molecular pathogenesis, diagnosis,and treatment. Int J Nephrol Renovasc Dis 2018; 11: 313-319. doi: 10.2147/IJNRD.S162071.

  2. Schirmer JH, Wright MN, Vonthein R, Herrmann K, Nölle B,Both M, et al. Clinical presentation and long-term outcomeof 144 patients with microscopic polyangiitis in a monocentricGerman cohort. Rheumatology (Oxford) 2016; 55(1): 71-79. doi: 10.1093/rheumatology/kev286.

  3. Jennette J, Falk R. Necrotizing arteritis and small vesselvasculitis. Autoimmune Dis 2007: 899-920.

  4. Lazarus B, John GT, O’Callaghan C, Ranganathan D. Recentadvances in anti-neutrophil cytoplasmic antibody-associatedvasculitis. Indian J Nephrol 2016; 26 (2): 86-96. doi:10.4103/0971-4065.171225.

  5. Watts RA, Lane S, Scott G. What is known about the epidemiologyof the vasculitides? Best Pract Res Clin Rheumatol2005; 19 (2): 191-207. doi: 10.1016/j.berh.2004.11.006.

  6. Pendergraft WF, Niles JL. Trojan horses: drug culpritsassociated with antineutrophil cytoplasmic autoantibody(ANCA) vasculitis. Curr Opin Rheumatol 2014; 26 (1): 42-49.doi: 10.1097/BOR.0000000000000014.

  7. Tsuchiya N. Genetics of microscopic polyangiitis in thejapanese population. Ann Vasc Dis 2012; 5 (3): 289-295.doi: 10.3400/avd.ra.12.00062.

  8. Geetha D, Jefferson JA. ANCA-Associated Vasculitis: CoreCurriculum 2020. Am J Kidney Dis 2020; 75 (1): 124-137.doi: 10.1053/j.ajkd.2019.04.031.

  9. Prendecki M, Pusey CD. Recent advances in understandingof the pathogenesis of ANCA-associated vasculitis.F1000Res 2018; 7: F1000 Faculty Rev-1113. doi: 10.12688/f1000research.14626.1

  10. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS,Travis WD, Rottem M, Fauci AS. Wegener granulomatosis:An analysis of 158 patients. Ann Intern Med 1992; 116 (6):488-498. doi: 10.7326/0003-4819-116-6-488.

  11. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis:Prospective clinical and therapeutic experiencewith 85 patients for 21 years. Ann Intern Med 1983; 98(1): 76-85. doi: 10.7326/0003-4819-98-1-76.

  12. Villiger PM, Guillevin L. Microscopic polyangiitis: Clinicalpresentation. Autoimmun Rev 2010; 9 (12): 812-819. doi:10.1016/j.autrev.2010.07.009.

  13. Poon SH, Baliog CR, Sams RN, Robinson-Bostom L, TelangGH, Reginato AM. Syndrome of cocaine-levamisoleinducedcutaneous vasculitis and immune-mediatedleukopenia. Semin Arthritis Rheum 2011; 41 (3); 434-444.doi: 10.1016/j.semarthrit.2011.05.009.

  14. Lichtenberger JP, Digumarthy SR, Abbott GF, Shepard JA,Sharma A. Diffuse pulmonary hemorrhage: Clues to thediagnosis. Curr Probl Diagn Radiol 2014; 43 (3): 128-139.doi: 10.1067/j.cpradiol.2014.01.002.

  15. Guérin C, Thompson T, Brower R. The ten diseases that looklike ARDS. Intensive Care Med 2015; 41 (6): 1099-1102. doi:10.1007/s00134-014-3608-x.

  16. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest2010; 137 (5): 1164-1171. doi: 10.1378/chest.08-2084.

  17. Albelda SM, Gefter WB, Epstein DM, Miller WT. Diffusepulmonary hemorrhage: A review and classification.Radiology 1985; 154 (2): 289-297. doi: 10.1148/radiology.154.2.3155569.

  18. Castañer E, Alguersuari A, Gallardo X, Andreu M, Pallardó Y,Mata JM, Ramírez J. When to suspect pulmonary vasculitis:Radiologic and clinical clues. Radiographics 2010; 30 (1):33-53. doi: 10.1148/rg.301095103.

  19. Brown KK. Pulmonary vasculitis. Proc Am Thorac Soc 2006;3 (1): 48-57. doi: 10.1513/pats.200511-120JH.

  20. Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, JohK, et al. Histopathologic classification of ANCA-associatedglomerulonephritis. J Am Soc Nephrol 2010; 21 (10): 1628-1636. doi: 10.1681/ASN.2010050477.

  21. Galeazzi M, Morozzi G, Sebastiani GD, Bellisai F, MarcolongoR, Cervera R, De Ramòn-Garrido E, et al. Anti-neutrophilcytoplasmic antibodies in 566 European patients withsystemic lupus erythematosus: prevalence, clinical associationsand correlation with other autoantibodies. EuropeanConcerted Action on the Immunogenetics of SLE. Clin ExpRheumatol 16 (5): 541-6.

  22. Omotoso BA, Cathro HP, Balogun R. Crescentic glomerulonephritiswith dual positive anti-GBM and C-ANCA/PR3antibodies. Clin Nephrol Case Stud 2016; 4: 5-10.2016. doi:10.5414/CNCS108666.

  23. De Groot K, Harper L, Jayne D, Flores-Suarez LF, Gregorini G,Gross WL, et al. Pulse versus daily oral cyclophosphamidefor induction of remission in antineutrophil cytoplasmicantibody-associated vasculitis: A randomized trial. AnnIntern Med 2009; 150 (10): 670-80. doi: 10.7326/0003-4819-150-10-200905190-00004.

  24. Harper L, Morgan MD, Walsh M, Hoglund P, Westman K,Flossmann O, et al. Pulse versus daily oral cyclophosphamidefor induction of remission in ANCA-associated vasculitis:Long-term follow-up. Ann Rheum Dis 2012; 71 (6): 955-960.doi: 10.1136/annrheumdis-2011-200477.

  25. Jones RB, Cohen-Tervaert JW, Hauser T, Luqmani R, MorganMD, Peh CA, et al. Rituximab versus cyclophosphamide inANCA-associated renal vasculitis. N Engl J Med 2010; 363(3): 211-220. doi: 10.1056/NEJMoa0909169.

  26. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, HoffmanGA, et al. Rituximab versus cyclophosphamide for ANCAassociatedvasculitis. N Engl J Med 2010; 363 (3): 221-232.doi: 10.1056/NEJMoa0909905.

  27. Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, BroganP, Bruchfeld A, et al. Mycophenolate mofetil versus cyclophosphamidefor remission induction in ANCA-associatedvasculitis: A randomised, non-inferiority trial. Ann RheumDis 2019; 78 (3): 399-405. doi: 10.1136/annrheumdis-2018-214245.

  28. Tuin J, Stassen PM, Bogdan DI, Broekroelofs J, van PaassenP, Cohen Tervaert JW, et al. Mycophenolate mofetil versuscyclophosphamide for the induction of remission innonlife-threatening relapses of antineutrophil cytoplasmicantibody-associated vasculitis: Randomized, controlledtrial. Clin J Am Soc Nephrol 2019; 14 (7): 1021-1028. doi:10.2215/CJN.11801018.

  29. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, FerrarioF, Guillevin L, et al. Randomized trial of plasma exchangeor high-dosage methylprednisolone as adjunctive therapyfor severe renal vasculitis. J Am Soc Nephrol 2007; 18 (7):2180-2188. doi: 10.1681/ASN.2007010090.

  30. Solar-Cafaggi D, Atisha-Fregoso Y, Hinojosa-Azaola A.Plasmapheresis therapy in ANCA-associated vasculitides:A single-center retrospective analysis of renal outcomeand mortality. J Clin Apher 2016; 31 (5): 411-418. doi:10.1002/jca.21415.

  31. Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, FujimotoS, et al. Plasma exchange and glucocorticoids insevere ANCA-associated vasculitis. N Engl J Med 2020; 382:622-631. doi: 10.1056/NEJMoa1803537.

  32. Derebail VK, Falk RJ. ANCA-Associated vasculitis-refiningtherapy with plasma exchange and glucocorticoids. N Engl JMed 2020; 382 (7): 671-673. doi: 10.1056/NEJMe1917490.

  33. Jayne DR, Bruchfeld AN, Harper L, Schaier M, Venning MC,Hamilton P, et al. Randomized trial of C5a receptor inhibitoravacopan in ANCA-associated vasculitis. J Am Soc Nephrol2017; 28 (9): 2756-2767. doi: 10.1681/ASN.2016111179.

  34. Rawal G, Kumar R, Yadav S. ECMO rescue therapy in diffusealveolar haemorrhage: a case report with review of literature.J Clin Diagn Res 2016; 10 (6): OD10-1.. doi: 10.7860/JCDR/2016/20649.7969.

  35. Choi GH, Kang M. Successful use of extracorporeal membraneoxygenation in diffuse alveolar hemorrhage secondaryto systemic lupus erythematosus. Korean J Crit CareMed 2016; 31 (4): 364-368. DOI: https://doi.org/10.4266/kjccm.2016.00451

  36. Abrams D, Agerstrand CL, Biscotti M, Burkart KM, BacchettaM, Brodie D. Extracorporeal membrane oxygenation in themanagement of diffuse alveolar hemorrhage. ASAIO J 2015;61 (2): 216-218. doi: 10.1097/MAT.0000000000000183.

  37. Quintana LF, Perez NS, De Sousa E, Rodas LM, GriffithsMH, Solé M, Jayne D. ANCA serotype and histopathologicalclassification for the prediction of renal outcomein ANCA-associated glomerulonephritis. Nephrol DialTransplant 2014; 29 (9): 1764-1769. doi: 10.1093/ndt/gfu084.




2020     |     www.medigraphic.com